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Correction
In the article [1] there were errors in Tables three, four,
five, six and seven. The incorrect values were produced
due to typographical errors during translation stage.
These errors affect neither the published discussion nor
the conclusions of the paper. However, a few changes to
the results section are detailed here.
In the Abstract, under “Results” the first two
sentences read
“The positive rate of EGFR protein in NSCLC tumor
cells was 46%, which was significantly higher than its
expression in normal lung (p = 0.0234) and paracancer-
ous tissues (p = 0.020). EGFR expression was signifi-
cantly higher in nodal positive than in nodal negative
patients (p = 0.04).”
But should have been:
“T h ep o s i t i v er a t eo fE G F Rp r o t e i ni nN S C L Ct u m o r
cells was 46%, which was significantly higher than its
expression in normal lung (p = 0.034) and paracancer-
ous tissues (p = 0.020). EGFR expression was signifi-
cantly higher in nodal positive than in nodal negative
patients (p = 0.006).”
In the main “Results” section of the article
The sentence under the heading “EGFR protein expres-
sion“ read: “T h ep o s i t i v er a t eo fE G F Rp r o t e i ni n
NSCLC tumor cells were 46%, which was significantly
higher than its expression in normal lung (p = 0.0234)
and paracancerous (p = 0.020)”
Which should have been:
“T h ep o s i t i v er a t eo fE G F Rp r o t e i ni nN S C L Ct u m o r
cells were 46%, which was significantly higher than its
expression in normal lung (p = 0.034) and paracancer-
ous (p = 0.020)”
Under the heading “Correlation between EGFR
expression and clinical features“ The second sentence
read: “It shows that the difference of EGFR expression
was only significant between the nodal positive and
negative subgroups (56.4% vs.10%, p = 0.04).”
But the passage should have been “The expression of
EGFR in different subgroups were compared and sum-
marized in Table three. It shows that the difference of
EGFR expression was only significant between the nodal
positive and negative subgroups (56.4% vs. 9.1%, p =
0.006). There is no significant difference between age
(60 vs. under 60 ys), gender, adeno- vs. non-adenocarci-
noma, the differentiation of tumor, and staging.”
This is the correct table three (table 1).
Correct tables four (table 2), five (table 3) and six
(table 4).
Under the heading “Correlation of EGFR and COX-2
expression“ The sentence reads: “A ss h o w ni nT a b l e
seven, no correlation was found between COX-2 and
EGFR protein expression (Χ2 = 0.112, P = 0.555).”
But should have read: “A ss h o w ni nT a b l es e v e n ,n o
correlation was found between COX-2 and EGFR pro-
tein expression (P > 0.05).”
Correct table seven (Table 5).
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Table 2 (corrected table four) COX-2 expression in
neoplastic and normal tissue
Tissue type Number
of cases
COX-2 Positive
rate(%)
P
value
positive negative
Neoplastic
tissue
50 45 5 90 0.000*
Normal
tissue
60 60
P < 0.05.
Table 3 (corrected table five) COX-2 expression in tumor
and paracancerous tissue
Tissue type Number of
cases
COX-2 Positive
rate(%)
P
value
positive negative
Neoplastic
tissue
50 45 5 90 0.000*
Paracancerous
tissue
7 1 6 14.3
P < 0.05.
Table 5 (corrected table seven) Correlation of EGFR and
COX-2 protein expression
EGFR Total
negative Positive
COX-2 negative 3 2 5
positive 24 21 45
Total 27 23 50
There was no significant relationship between COX-2 and EGFR. P > 0.05.
Table 4 (corrected table six) 6 COX-2 expression and
correlation with clinical features
Clinical features COX-2 Positive
expression rate
P
value
negative positive
Ages 0.599
≤60 3 30 90.90%
> 60 2 15 88.20%
Sex 0.362
Male 4 27 87.10%
Female 1 18 94.70%
Pathologic type 0.022*
Squamous carcinoma 5 16 76.20%
Adencarcinoma 0 26 100%
Mixed type 0 3 100%
Tumor length 0.518
≤3 cm 2 14 87.50%
> 3 cm 3 31 91.20%
Level of Differentiation 0.258
Poor Differentiated 2 8 80%
Moderate and Well
Differentiated
3 37 92.50%
TNM Stage 0.476
I-II 2 13 86.70%
III-IV 3 32 91.40%
Lymph node 0.699
N0 1 10 90.90%
N1-3 4 35 89.70%
*P < 0.05.
Table 1 (corrected table 3). EGFR expression and clinical
characteristics
Clinical features EGFR Positive
expression rate
P
value
negative positive
Ages 0.448
< 60 18 14 43.80%
≥60 9 9 50%
Sex 0.445
Male 16 15 48.40%
Female 11 8 42.10%
Pathologic type 0.543
Squamous carcinoma 13 8 38.10%
Adencarcinoma 13 13 50.0%
Mixed type 1 2 66.70%
Tumor length 0.535
≤3 cm 9 7 43.80%
> 3 cm 18 16 47.10%
Level of Differentiation 0.474
Poor Differentiated 6 4 40%
Moderate and Well
Differentiated
21 19 47.50%
TNM Stage 0.194
I-II 10 5 33.30%
III-IV 17 18 51.40%
Lymph node 0.006*
N0 10 1 9.10%
N1-3 17 22 56.40%
*P < 0.05.
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